Lidia Usnarska-Zubkiewicz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5216437/publications.pdf

Version: 2024-02-01

50	442	11	18
papers	citations	h-index	g-index
53	53	53	925
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Central nervous system involvement by multiple myeloma: A multiâ€institutional retrospective study of 172 patients in daily clinical practice. American Journal of Hematology, 2016, 91, 575-580.	2.0	83
2	Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy. Oncotarget, 2016, 7, 56726-56736.	0.8	58
3	Hematogenous extramedullary relapse in multiple myeloma ―a multicenter retrospective study in 127 patients. American Journal of Hematology, 2019, 94, 1132-1140.	2.0	24
4	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leukemia and Lymphoma, 2019, 60, 118-123.	0.6	23
5	Characteristics and outcomes of patients with multiple myeloma aged 21–40Âyears versus 41–60Âyears: a multiâ€institutional caseâ€control study. British Journal of Haematology, 2016, 175, 884-891.	1.2	21
6	Heart Rate Variability and Heart Rate Turbulence in Patients with Hematologic Malignancies Subjected to Highâ€Dose Chemotherapy in the Course of Hematopoietic Stem Cell Transplantation. Annals of Noninvasive Electrocardiology, 2014, 19, 157-165.	0.5	16
7	Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma. Advances in Medical Sciences, 2019, 64, 349-355.	0.9	16
8	The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide,) Tj ETQq0 0 0 rgBT /OvGroup. Leukemia Research, 2010, 34, 1330-1335.	verlock 10 0.4	Tf 50 467 Td 14
9	Review Bortezomib-induced painful neuropathy in patients with multiple myeloma. Wspolczesna Onkologia, 2013, 5, 421-426.	0.7	12
10	Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. Leukemia and Lymphoma, 2017, 58, 2089-2100.	0.6	12
11	Monoclonal gammopathy of renal significance (MGRS): Realâ€world data on outcomes and prognostic factors. American Journal of Hematology, 2022, 97, 877-884.	2.0	12
12	A multicenter retrospective study of 223 patients with $t(14;16)$ in multiple myeloma. American Journal of Hematology, 2020, 95, 503-509.	2.0	11
13	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2016. Acta Haematologica Polonica, 2016, 47, 39-85.	0.1	10
14	Endothelial Function in Patients with Hematologic Malignancies Undergoing High-Dose Chemotherapy Followed by Hematopoietic Stem Cell Transplantation. Cardiovascular Toxicology, 2016, 16, 156-162.	1.1	10
15	Soluble Urokinase-Type Plasminogen Activator Receptor and Ferritin Concentration in Patients with Advanced Alimentary Tract Carcinoma. Relationship to Localization, Surgical Treatment and the Stage of the Disease – Preliminary Report. Advances in Clinical and Experimental Medicine, 2014, 23, 959-967.	0.6	10
16	Abnormal Distribution of Gamma-Delta T Lymphocytes and Their Subsets in Type 1 Diabetes. Advances in Clinical and Experimental Medicine, 2016, 25, 665-671.	0.6	10
17	Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients. International Journal of Molecular Sciences, 2021, 22, 9298.	1.8	8
18	Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma. Cells, 2021, 10, 411.	1.8	7

#	Article	IF	CITATIONS
19	Real-life experience with bortezomib-based regimens in elderly comorbid patients with newly diagnosed multiple myeloma – Polish retrospective multicenter analysis. Polish Archives of Internal Medicine, 2017, 127, 765-774.	0.3	7
20	The analysis of the parameters of 24â€hr <scp>ECG</scp> Holter monitoring in patients with blood neoplasms undergoing highâ€dose chemotherapy and stem cell transplantation. Annals of Noninvasive Electrocardiology, 2018, 23, e12534.	0.5	6
21	Primary refractory multiple myeloma: a real-world experience with 85 cases. Leukemia and Lymphoma, 2020, 61, 2868-2875.	0.6	6
22	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄce rozpoznawania i leczenia szpiczaka plazmocytowego na rok 2012. Acta Haematologica Polonica, 2012, 43, 7-47.	0.1	5
23	Zalecenia Polskiej Grupy Szpiczakowej dotyczäce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2017. Acta Haematologica Polonica, 2017, 48, 55-103.	0.1	5
24	Molecular Characterization of Mouse Monoclonal Antibody BIII. 136 and the Epitope Recognized by the Antibody in Human Band 3 Protein. Hybridoma, 1995, 14, 217-223.	0.9	4
25	Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective—A report by Polish Myeloma Study Group. Leukemia Research, 2014, 38, 788-794.	0.4	4
26	Risk factors and causes for early mortality in patients with newly diagnosed multiple myeloma in a "real world" study: experiences of the Polish Myeloma Group. Polish Archives of Internal Medicine, 2021, 131, 527-534.	0.3	4
27	Platelet polyphosphate level is elevated in patients with chronic primary thrombocytopenia: A preliminary study. Advances in Clinical and Experimental Medicine, 2020, 29, 1051-1056.	0.6	4
28	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2018/2019. Acta Haematologica Polonica, 2018, 49, 157-206.	0.1	4
29	High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group. Oncology Letters, 2019, 18, 5811-5820.	0.8	4
30	Echocardiographic evaluation of the early cardiotoxic effect of hematopoietic stem cell transplantation in patients with hematologic malignancies. Leukemia and Lymphoma, 2016, 57, 2119-2125.	0.6	3
31	Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patientsâ€"Report of the Polish Myeloma Group. Leukemia Research, 2016, 40, 90-99.	0.4	3
32	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leukemia and Lymphoma, 2020, 61, 1885-1893.	0.6	3
33	The Prognostic Impact of $t(14;16)$ in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. Blood, 2018, 132, 4452-4452.	0.6	3
34	Analysis of Free Serum Light Chains in Patients Suffering from Multiple Myeloma Complicated by Light-Chain Amyloidosis. Advances in Clinical and Experimental Medicine, 2014, 23, 531-538.	0.6	3
35	Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis. Haematologica, 2021, 106, 601-604.	1.7	2
36	The Occurrence of AL Amyloidosis (Light-Chain Amyloidosis) in Patients with Multiple Myeloma in Lower Silesia Region, Poland. Advances in Clinical and Experimental Medicine, 2014, 23, 235-244.	0.6	2

#	Article	IF	CITATIONS
37	Pregnancy in a woman with polycystic ovary syndrome and myelodysplastic syndrome (in the form of) Tj ETQq1 1	0.784314 0.7	rgBT /Overl
07	Gynecological Endocrinology, 2010, 26, 135-138.	0.7	
38	Evaluation of the impact of treatment with hematopoietic stem cells transplantation (HSCT) on biochemical markers of heart function and novel electrocardiographic markers of repolarization in patients with hematological malignancies. Medical Oncology, 2018, 35, 162.	1.2	1
39	Platelet Reactivity and Response to Aspirin and Clopidogrel in Patients with Platelet Count Disorders. Cardiology Research and Practice, 2021, 2021, 1-7.	0.5	1
40	Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients. Blood, 2018, 132, 2004-2004.	0.6	1
41	Autologous stem cell transplantation in the treatment of multiple myeloma patients with 17p deletion. Polish Archives of Internal Medicine, 2020, 130, 106-111.	0.3	1
42	Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group. Journal of Clinical Medicine, 2021, 10, 5504.	1.0	1
43	Dziesięciolecie Polskiej Grupy Szpiczakowej – historia i osiągnięcia. Acta Haematologica Polonica, 2015, 212-223.	46.1	O
44	Quality of life assessment in multiple myeloma patients – preliminary report. Palliative Medicine, 2018, 10, 208-215.	0.1	0
45	An asymptomatic course of SARS-CoV-2 infection in a patient with three different neoplasms and treated with bortezomib $\hat{a}\in$ a coincidence or new therapeutic possibility. Polish Archives of Internal Medicine, 2021, 131, 747-748.	0.3	O
46	Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma (MM) Patients: a Preliminary Report of Polish Myeloma Group. Blood, 2011, 118, 5125-5125.	0.6	0
47	Impact of Anthracycline-Based Induction Chemotherapy on the Calreticulin, CD47 Exposure and the Percentage of Regulatory T Cells in Patients with Acute Leukemias: Preliminary Study. Blood, 2014, 124, 5259-5259.	0.6	О
48	Altered Endothelial Cells Properties and Platelets Activity in Treatment NaÃ'Ve Patients with Multiple Myeloma (MM) and Non-Hodgkin Lymphoma (nHL): Association with Thromboembolic Complications. Blood, 2016, 128, 5649-5649.	0.6	0
49	Ascites in the Course of Plasma Cell Myeloma Complicated by AL Amyloidosis. Turkish Journal of Haematology, 2018, 35, 71-72.	0.2	О
50	Early Mortality in Patients with Multiple Myeloma Treated with Novel Agents - Analysis from Polish Myeloma Study Group. Blood, 2020, 136, 36-37.	0.6	0